Abstract
Sensitive to the massive diffusion of purported metabolic and cardiovascular positive effects of green tea and catechincontaining extracts, many consumers of cardiovascular drugs assume these products as a “natural” and presumably innocuous adjunctive way to increase their overall health. However, green tea may interfere with the oral bioavailability or activity of cardiovascular drugs by various mechanisms, potentially leading to reduced drug efficacy or increased drug toxicity. Available data about interactions between green tea and cardiovascular drugs in humans, updated in this review, are limited so far to warfarin, simvastatin and nadolol, and suggest that the average effects are mild to modest. Nevertheless, in cases of unexpected drug response or intolerance, it is warranted to consider a possible green tea-drug interaction, especially in people who assume large volumes of green tea and/or catechin-enriched products with the conviction that “more-is-better”.
Keywords: Green tea, herb-drug interaction, dietary-drug interaction, catechins, simvastatin, warfarin, nadolol, cardiovascular drugs.
Current Pharmaceutical Design
Title:Overview of Green Tea Interaction with Cardiovascular Drugs
Volume: 21 Issue: 9
Author(s): Jose P. Werba, Shingen Misaka, Monica G. Giroli, Shizuo Yamada, Viviana Cavalca, Keisuke Kawabe, Isabella Squellerio, Federica Laguzzi, Satomi Onoue, Fabrizio Veglia, Veronika Myasoedova, Kazuhiko Takeuchi, Eisuke Adachi, Naoki Inui, Elena Tremoli and Hiroshi Watanabe
Affiliation:
Keywords: Green tea, herb-drug interaction, dietary-drug interaction, catechins, simvastatin, warfarin, nadolol, cardiovascular drugs.
Abstract: Sensitive to the massive diffusion of purported metabolic and cardiovascular positive effects of green tea and catechincontaining extracts, many consumers of cardiovascular drugs assume these products as a “natural” and presumably innocuous adjunctive way to increase their overall health. However, green tea may interfere with the oral bioavailability or activity of cardiovascular drugs by various mechanisms, potentially leading to reduced drug efficacy or increased drug toxicity. Available data about interactions between green tea and cardiovascular drugs in humans, updated in this review, are limited so far to warfarin, simvastatin and nadolol, and suggest that the average effects are mild to modest. Nevertheless, in cases of unexpected drug response or intolerance, it is warranted to consider a possible green tea-drug interaction, especially in people who assume large volumes of green tea and/or catechin-enriched products with the conviction that “more-is-better”.
Export Options
About this article
Cite this article as:
Werba P. Jose, Misaka Shingen, Giroli G. Monica, Yamada Shizuo, Cavalca Viviana, Kawabe Keisuke, Squellerio Isabella, Laguzzi Federica, Onoue Satomi, Veglia Fabrizio, Myasoedova Veronika, Takeuchi Kazuhiko, Adachi Eisuke, Inui Naoki, Tremoli Elena and Watanabe Hiroshi, Overview of Green Tea Interaction with Cardiovascular Drugs, Current Pharmaceutical Design 2015; 21 (9) . https://dx.doi.org/10.2174/1381612820666141013135045
DOI https://dx.doi.org/10.2174/1381612820666141013135045 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Association of Low Vitamin D with Complications of HIV and AIDS: A literature Review
Infectious Disorders - Drug Targets Prostacyclin, Atherothrombosis and Diabetes Mellitus: Physiologic and Clinical Considerations
Current Molecular Medicine Impact of Sex on Office White Coat effect Tail: A Review
Current Pharmaceutical Design Chronic Immune Stimulation Correlates with Reduced Phenylalanine Turnover
Current Drug Metabolism Phytotherapy for the Prevention of Atherosclerosis-Associated Early Cerebral Ischemia
Current Drug Metabolism Discovering Natural Product Modulators to Overcome Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Biotechnology Relationship of High-Sensitivity C-Reactive Protein Concentrations and Systolic Heart Failure
Current Vascular Pharmacology Thiazide Diuretics: 50 Years and Beyond
Current Hypertension Reviews The Role of Mass Spectrometry in the “Omics” Era
Current Organic Chemistry Aspartic Proteinases in Disease: A Structural Perspective
Current Drug Targets Current Status of Rho-Associated Kinases (ROCKs) in Coronary Atherosclerosis and Vasospasm
Cardiovascular & Hematological Agents in Medicinal Chemistry Recent Progress Toward Hydrogen Medicine: Potential of Molecular Hydrogen for Preventive and Therapeutic Applications
Current Pharmaceutical Design Neuroprotective Effects of Quercetin: From Chemistry to Medicine
CNS & Neurological Disorders - Drug Targets Peripheral Arterial Disease: The Magnitude of the Problem and its Socioeconomic Impact
Current Drug Targets - Cardiovascular & Hematological Disorders The Relationship Between Personality Types and Sexual Dysfunction
Current Women`s Health Reviews Flavonoids: Prospective Drug Candidates
Mini-Reviews in Medicinal Chemistry Editorial [Hot Topic Cells, Micro- and Nanosystems in Reconstructive Medicine: Past, Present, and Future Guest Editors: Christian Andressen & Andreas Wree]
Current Pharmaceutical Biotechnology Endothelin and the Ischaemic Heart
Current Vascular Pharmacology Myocardial Energetics in Left Ventricular Hypertrophy
Current Cardiology Reviews Diabetic Peripheral Neuropathy: Diagnosis and Treatment
Current Drug Safety